絞り込み

17077

広告

「"Chmielowski B "[Author]」の検索結果

98件中 41件~60件表示    検索結果をPubMedで見る PubMedで見る

Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-1L antibodies.

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.

CRAF R391W is a melanoma driver oncogene.

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.

PD-1 blockade expands intratumoral T memory cells.

A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas.

Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab.

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.

Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression.

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma.

PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Risk stratification of patients undergoing pulmonary metastasectomy for soft tissue and bone sarcomas.

Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA.

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
Sort by
※並べ替えは表示に時間がかかります